Dynavax Technologies Corp

Find Ratings Reports
DVAX : NASDAQ : Health Care
$16.2 up 0.05 | 0.31%
Today's Range: 15.95 - 16.35
Avg. Daily Volume: 3165200.0
08/23/17 - 4:00 PM ET

Financial Analysis


DYNAVAX TECHNOLOGIES CORP's gross profit margin for the second quarter of its fiscal year 2017 has significantly decreased when compared to the same period a year ago. Even though sales decreased, the net income has increased.

At the same time, stockholders' equity ("net worth") has remained virtually unchanged only increasing by 1.26% from the same quarter last year.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. To learn more visit www.TheStreetRatings.com.



Income Statement Q2 FY17 Q2 FY16
Net Sales ($mil)0.112.65
EBITDA ($mil)0.0-28.71
EBIT ($mil)-20.32-29.25
Net Income ($mil)-20.32-28.99


Balance Sheet Q2 FY17 Q2 FY16
Cash & Equiv. ($mil)126.96138.99
Total Assets ($mil)151.97167.61
Total Debt ($mil)0.00.0
Equity ($mil)140.53138.77


Profitability Q2 FY17 Q2 FY16
Gross Profit Margin-19353.33-1084.62
EBITDA Margin0.0-1084.62
Operating Margin-19353.33-1105.18
Sales Turnover0.050.03
Return on Assets-67.14-67.41
Return on Equity-72.61-81.42
Debt Q2 FY17 Q2 FY16
Current Ratio0.05.21
Debt/Capital0.00.0
Interest Expense0.00.0
Interest Coverage0.00.0


Share Data Q2 FY17 Q2 FY16
Shares outstanding (mil)0.038.5
Div / share0.00.0
EPS-0.41-0.75
Book value / share0.03.6
Institutional Own % n/a n/a
Avg Daily Volume2964805.01358149.0

Valuation


SELL. This stock’s P/E ratio is negative, making its value useless in the assessment of premium or discount valuation, only displaying that the company has negative earnings per share. Due to the lack of price valuation ratios for DYNAVAX TECHNOLOGIES CORP, we cannot determine the premium or discount status of the shares at this time.


Price/Earnings
1 2 3 4 5
premium   discount
  Price/Cash Flow
1 2 3 4 5
premium   discount
DVAX NM Peers 37.70   DVAX NA Peers 25.05

Neutral. The absence of a valid P/E ratio happens when a stock can not be valued on the basis of a negative stream of earnings.

DVAX's P/E is negative making this valuation measure meaningless.

 

Neutral. The P/CF ratio is the stock’s price divided by the sum of the company's cash flow from operations. It is useful for comparing companies with different capital requirements or financing structures.

Ratio not available.

 
Price/Projected
Earnings
1 2 3 4 5
premium   discount
  Price to
Earnings/Growth
1 2 3 4 5
premium   discount
DVAX NM Peers 24.88   DVAX NA Peers 0.44

Neutral. The absence of a valid price-to-projected earnings ratio happens when a stock can not be valued on the basis of a negative expected future earnings.

DVAX's ratio is negative making this valuation measure meaningless.

 

Neutral. The PEG ratio is the stock’s P/E divided by the consensus estimate of long-term earnings growth. Faster growth can justify higher price multiples.

Ratio not available.

 
Price/Book
1 2 3 4 5
premium   discount
  Earnings Growth
1 2 3 4 5
lower   higher
DVAX NA Peers 10.65   DVAX 16.84 Peers 12.57

Neutral. A lower price-to-book ratio makes a stock more attractive to investors seeking stocks with lower market values per dollar of equity on the balance sheet.

Ratio not available.

 

Higher. Elevated earnings growth rates can lead to capital appreciation and justify higher price-to-earnings ratios.

DVAX is expected to have an earnings growth rate that significantly exceeds its peers.

 
Price/Sales
1 2 3 4 5
premium   discount
  Sales Growth
1 2 3 4 5
premium   discount
DVAX NA Peers 143.41   DVAX 41.10 Peers 358.36

Neutral. In the absence of P/E and P/B multiples, the price-to-sales ratio can display the value investors are placing on each dollar of sales.

Ratio not available.

 

Lower. A sales growth rate that trails the industry implies that a company is losing market share.

DVAX significantly trails its peers on the basis of sales growth

 

 

Latest Stock Upgrades/Downgrades